The present invention relates to a compound for an organic optoelectronic device, represented by Chemical Formula 1; a composition for an organic optoelectronic device, including same; an organic optoelectronic device; and a display device. The description of Chemical Formula 1 is the same as that defined in the specification.

The present invention relates to a compound for an organic optoelectronic device, represented by Chemical Formula 1; a composition for an organic optoelectronic device, including same; an organic optoelectronic device; and a display device. The description of Chemical Formula 1 is the same as that defined in the specification.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V and formula VI and the methods for the treatment of eye disorders and skin diseases and may be formulated for the topical eye drop, topical paste, ocular solution, device-drug delivery, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, cream, dermal ointment, gels, lotions, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of skin diseases such as acne, rosacea and eye disorders such as ocular redness, glaucoma, presbyopia, IOP, cataract, dry eye and oGVHD.

Disclosed are a [1,2,4]triazolo[1,5-a]pyridine compound as JAK inhibitor and an application thereof in preparing a drug for treating a disease related to JAK or/and TYK2. Specifically, the present invention relates to a compound represented by formula (I), or an isomer or pharmaceutically acceptable salt thereof. (I)

##STR00001##

An organic molecule is disclosed having: a first chemical unit comprising or consisting of a structure according to formula I ##STR00001##
and two second chemical moieties, each at each occurrence independently from another comprising or consisting of a structure of formula II, ##STR00002##
wherein the first chemical moiety is linked to each of the two second chemical moieties via a single bond.

Disclosed in the present invention are a compound represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt, and applications thereof in the preparation of drugs for treating HBV-related diseases. ##STR00001##

A compound represented by Formula [3] or a salt thereof and a method of making the same,

##STR00001## in the formula, L.sup.3 represents a group represented by Formula [2c]

##STR00002##

wherein R.sup.3c, R.sup.4c, R.sup.5c, and R.sup.6c are the same as or different from each other and represent a hydrogen atom or a C.sub.1-6 alkyl group; p.sup.3 represents an integer of 1 to 3; q.sup.3 represents an integer of 0 to 3; and r.sup.3 represents an integer of 1 to 6; A.sup.1 represents any one of the groups represented by Formulae [4] to [9],

##STR00003## wherein * represents a binding position; and R.sup.7 represents a carboxyl-protecting group; and m represents an integer of 1 to 3.

A compound represented by Formula [3] or a salt thereof and a method of making the same,

##STR00001## in the formula, L.sup.3 represents a group represented by Formula [2c]

##STR00002##

wherein R.sup.3c, R.sup.4c, R.sup.5c, and R.sup.6c are the same as or different from each other and represent a hydrogen atom or a C.sub.1-6 alkyl group; p.sup.3 represents an integer of 1 to 3; q.sup.3 represents an integer of 0 to 3; and r.sup.3 represents an integer of 1 to 6; A.sup.1 represents any one of the groups represented by Formulae [4] to [9],

##STR00003## wherein * represents a binding position; and R.sup.7 represents a carboxyl-protecting group; and m represents an integer of 1 to 3.

The present disclosure relates to uses of TG02, for treating a glioma in a pediatric human subject. In certain embodiments, the glioma can be a pediatric high-grade glioma (PHGG), e.g., a diffuse intrinsic pontine glioma (DIPG), and/or a H3.3-mutated glioma (e.g., a H3K27M-mutated glioma). The present disclosure further provides pharmaceutical compositions and kits that include an ERK5 inhibitor.

The present disclosure relates to antibody conjugates with binding specificity for folate receptor alpha (FOLR1) and its isoforms and homologs, and compositions comprising the antibody conjugates, including pharmaceutical compositions. The variable light chains are those of trastuzumab. Also provided are methods of producing the antibody conjugates and compositions as well as methods of using the antibody conjugates and compositions, such as in therapeutic and diagnostic methods. The antibody conjugates comprise a non-natural amino acid at a site selected from the group consisting of HC-F404, HC-K121, HC-Y180, HC-F241, HC-221, LC-T22, LC-S7, LC-N152, LC-K42, LC-E161, LC-D170, HC-S136, HC-S25, HC-A40, HC-S119, HC-S190, HC-K222, HC-R19, HC-Y52, or HC-S70, according to the Kabat, Chothia, or EU numbering scheme.